BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35618837)

  • 21. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
    Bret C; Viziteu E; Kassambara A; Moreaux J
    Expert Rev Hematol; 2016; 9(4):351-60. PubMed ID: 26761438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes.
    Gerber JM; Zeidner JF; Morse S; Blackford AL; Perkins B; Yanagisawa B; Zhang H; Morsberger L; Karp J; Ning Y; Gocke CD; Rosner GL; Smith BD; Jones RJ
    Haematologica; 2016 May; 101(5):607-16. PubMed ID: 26819054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
    Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Changes During Acute Myeloid Leukemia (AML) Evolution and Identification of Novel Treatment Strategies Through Molecular Stratification.
    Karjalainen E; Repasky GA
    Prog Mol Biol Transl Sci; 2016; 144():383-436. PubMed ID: 27865463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia.
    Kakiuchi S; Minami Y; Miyata Y; Mizutani Y; Goto H; Kawamoto S; Yakushijin K; Kurata K; Matsuoka H; Minami H
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
    Boila LD; Sengupta A
    Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
    Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
    J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
    Daver N; Cortes J; Kantarjian H; Ravandi F
    Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signal transduction in Acute Myeloid Leukemia - Implications for Novel Therapeutic Concepts.
    Konig H; Santos CD
    Curr Cancer Drug Targets; 2015; 15(9):803-21. PubMed ID: 26278711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
    Saygin C; Hu E; Zhang P; Sher S; Lozanski A; Doong TJ; Nicolet D; Orwick S; Labanowska J; Skinner JN; Cempre C; Kauffman T; Goettl VM; Heerema NA; Abruzzo L; Miller C; Lapalombella R; Behbehani G; Mims AS; Larkin K; Grieselhuber N; Walker A; Bhatnagar B; Bloomfield CD; Byrd JC; Lozanski G; Blachly JS
    Leukemia; 2021 Dec; 35(12):3406-3420. PubMed ID: 34021247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
    Goldberg L; Tijssen MR; Birger Y; Hannah RL; Kinston SJ; Schütte J; Beck D; Knezevic K; Schiby G; Jacob-Hirsch J; Biran A; Kloog Y; Marcucci G; Bloomfield CD; Aplan PD; Pimanda JE; Göttgens B; Izraeli S
    Blood; 2013 Oct; 122(15):2694-703. PubMed ID: 23974202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.